Supplementary Material (ESI) for Chemical Communications

This journal is (c) The Royal Society of Chemistry 2009

**Supporting Information For:** 

## Cu(II)-Mediated Oxidative Intermolecular *ortho* C-H Functionalisation Using Tetrahydropyrimidine as the Directing Group

Tsukasa Mizuhara, Shinsuke Inuki, Shinya Oishi, Nobutaka, Fujii\* and Hiroaki, Ohno\*

Graduate School of Pharmaceutical Sciences, Kyoto University Sakyo-ku, Kyoto 606-8501 (Japan) E-mail: hohno@pharm.kyoto-u.ac.jp; nfujii@pharm.kyoto-u.ac.jp

## **Table of Contents**

Experimental Section ------ S2

NMR Spectral Data ----- S8



General Procedure for Preparation of the Substrates.<sup>1</sup> Synthesis of 2-Phenyl-1,4,5,6-tetrahydropyrimidine (1a): To a solution of benzaldehyde (5.00 g, 47.1 mmol) in *t*-BuOH (470 mL) was added propylenediamine (3.84 g, 51.8 mmol). The mixture was stirred at 70 °C for 30 min, and then K<sub>2</sub>CO<sub>3</sub> (19.53 g, 141.3 mmol) and I<sub>2</sub> (14.95 g, 58.8 mmol) were added. After stirring at this temperature for 3 h, the mixture was quenched with sat. Na<sub>2</sub>SO<sub>3</sub> until the iodine color almost disappeared. The organic layer was separated and concentrated in vacuo. The resulting solid was recrystallised from MeOH–Et<sub>2</sub>O to give 2-phenyl-1,4,5,6-tetrahydropyrimidine hydroiodide. The resulting crystal was dissolved with H<sub>2</sub>O, and then pH was adjusted to 12–14 with 2N NaOH. The whole was extracted with CHCl<sub>3</sub>. The extract was dried over MgSO<sub>4</sub>. The filtrate was concentrated in vacuo, and the resulting solid was recrystallised from CHCl<sub>3</sub>–*n*-hexane to give the compound **1a** as colorless crystals (6.62 g, 82%): mp 88–89 °C (from CHCl<sub>3</sub>–*n*-hexane); IR (neat) cm<sup>-1</sup>: 1618 (C=N); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  1.83-1.85 (m, 2H, CH<sub>2</sub>), 3.49 (t, *J* = 5.9 Hz, 4H, 2 × CH<sub>2</sub>), 5.02 (br s, 1H, NH), 7.34-7.38 (m, 3H, Ar), 7.63-7.66 (m, 2H, Ar); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  20.7, 42.3 (2C), 126.0 (2C), 128.2 (2C), 129.6, 137.3, 154.5. *Anal.* calcd for C<sub>10</sub>H<sub>12</sub>N<sub>2</sub>: C, 74.97; H, 7.55; N, 17.48. Found; C, 74.79; H, 7.53; N, 17.43.

<sup>1</sup> M. Ishihara and H. Togo, *Tetrahedron*, 2007, **63**, 1474.



**2-(4-Methoxyphenyl)-1,4,5,6-tetrahydropyrimidine** (**1b**): *p*-Methoxybenzaldehyde (1.36 g, 10 mmol) was subjected to general procedure as described above. Colorless crystals (1.40 g, 74%): mp 132–134 °C (from CHCl<sub>3</sub>–*n*-hexane); IR (neat) cm<sup>-1</sup>: 1611 (C=N); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  1.81-1.87 (m, 2H, CH<sub>2</sub>), 3.49 (t, *J* = 5.7 Hz, 4H, 2 × CH<sub>2</sub>), 3.81 (s, 3H, OCH<sub>3</sub>), 4.87 (br s, 1H, NH), 6.86 (d, *J* = 9.4 Hz, 2H, Ar), 7.60 (d, *J* = 9.4 Hz, 2H, Ar); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  20.9, 42.4 (2C), 55.2, 113.5 (2C), 127.2 (2C), 130.0, 153.9, 160.6. *Anal.* calcd for C<sub>11</sub>H<sub>14</sub>N<sub>2</sub>O: C, 69.45; H, 7.42; N, 14.73. Found: C, 69.18; H, 7.46; N, 14.58.



**2-(4-Tolyl)-1,4,5,6-tetrahydropyrimidine** (**1c**): *p*-Tolualdehyde (1.20 g, 10 mmol) was subjected to general procedure as described above. Colorless crystals (1.03 g, 59%): mp 120–121 °C (from CHCl<sub>3</sub>–*n*-hexane); IR (neat) cm<sup>-1</sup>: 1615 (C=N); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  1.82-1.85 (m, 2H, CH<sub>2</sub>), 2.35 (s, 3H, CH<sub>3</sub>), 3.49 (t, *J* = 5.7 Hz, 4H, 2 × CH<sub>2</sub>), 4.90 (br s, 1H, NH), 7.15 (d, *J* = 8.3 Hz, 2H, Ar), 7.54 (d, *J* = 8.3 Hz, 2H, Ar); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  20.8, 21.2, 42.3 (2C), 125.8 (2C), 128.9 (2C), 134.5, 139.5, 154.3. *Anal.* calcd for C<sub>11</sub>H<sub>14</sub>N<sub>2</sub>: C, 75.82; H, 8.10; N, 16.08. Found: C, 75.76; H, 8.01; N,



**2-(4-Bromophenyl)-1,4,5,6-tetrahydropyrimidine** (**1d**): *p*-Bromobenzaldehyde (1.85 g, 10 mmol) was subjected to general procedure as described above. Colorless crystals (1.82 g, 76%): mp 174–175 °C (from CHCl<sub>3</sub>–*n*-hexane); IR cm<sup>-1</sup>: 1619 (C=N); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  1.81-1.88 (m, 2H, CH<sub>2</sub>), 3.49 (t, *J* = 5.7 Hz, 4H, 2 × CH<sub>2</sub>), 4.81 (br s, 1H, NH), 7.48 (d, *J* = 8.8 Hz, 2H, Ar), 7.53 (d, *J* = 8.8 Hz, 2H, Ar); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  20.7, 42.4 (2C), 123.8, 127.6 (2C), 131.4 (2C), 136.3, 153.5. *Anal.* calcd for C<sub>10</sub>H<sub>11</sub>BrN<sub>2</sub>: C, 50.23; H, 4.64; N, 11.72. Found: C, 50.20; H, 4.51; N, 11.66.



**Methyl 4-(1,4,5,6-Tetrahydropyrimidin-2-yl)benzoate** (1e): Methyl 4-formylbenzoate (1.00 g, 6.09 mmol) was subjected to general procedure as described above. Colorless crystals (1.63 g, 80%): mp 152–153 °C (from CHCl<sub>3</sub>–*n*-hexane); IR (neat) cm<sup>-1</sup>: 1721 (C=O), 1620 (C=N); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  1.83-1.89 (m, 2H, CH<sub>2</sub>), 3.52 (t, *J* = 5.7 Hz, 4H, 2 × CH<sub>2</sub>), 3.92 (s, 3H, OCH<sub>3</sub>), 5.04 (br s, 1H, NH), 7.72 (d, *J* = 8.5 Hz, 2H, Ar), 8.02 (d, *J* = 8.5 Hz, 2H, Ar); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  20.5, 42.3 (2C), 52.1, 126.0 (2C), 129.5 (2C), 130.8, 141.5, 153.6, 166.6. *Anal.* calcd for C<sub>12</sub>H<sub>14</sub>N<sub>2</sub>O<sub>2</sub>: C, 66.04; H, 6.47; N, 12.84. Found: C, 65.76; H, 6.28; N, 12.69.



**2-[4-(Trifluoromethyl)phenyl]-1,4,5,6-tetrahydropyrimidine** (**1f**): *p*-(Trifluolomethyl)benzaldehyde (1.74 g, 10 mmol) was subjected to general procedure as described above. Colorless crystals (1.71 g, 75%). mp 176–177 °C (from CHCl<sub>3</sub>–*n*-hexane); IR (neat) cm<sup>-1</sup>: 1620 (C=N); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  1.83-1.89 (m, 2H, CH<sub>2</sub>), 3.51 (t, *J* = 5.7 Hz, 4H, 2 × CH<sub>2</sub>), 4.92 (br s, 1H, NH), 7.61 (d, *J* = 8.3 Hz, 2H, Ar), 7.76 (d, *J* = 8.3 Hz, 2H, Ar); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  20.6, 42.4 (2C), 122.6, 125.2 (q, *J* = 3.7 Hz, 2C), 126.4 (2C), 131.4 (d, *J* = 32.3 Hz), 140.7, 153.3; <sup>19</sup>F NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  –62.6. *Anal.* calcd for C<sub>11</sub>H<sub>11</sub>F<sub>3</sub>N<sub>2</sub>: C, 57.89; H, 4.86; N, 12.28. Found: C, 57.89; H, 4.82; N, 12.29.



**2-(4-Nitrophenyl)-1,4,5,6-tetrahydropyrimidine** (**1g**): *p*-Nitrobenzaldehyde (1.51 g, 10 mmol) was subjected to general procedure as described above. Yellow crystals (1.63 g, 80%): mp 169–171 °C (from CHCl<sub>3</sub>–*n*-hexane); IR (neat) cm<sup>-1</sup>: 1623 (C=N), 1519 (NO<sub>2</sub>), 1339 (NO<sub>2</sub>); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ 

1.85-1.90 (m, 2H, CH<sub>2</sub>), 3.54 (t, J = 5.6 Hz, 4H, 2 × CH<sub>2</sub>), 5.08 (br s, 1H, NH), 7.83 (d, J = 9.1 Hz, 2H, Ar), 8.20 (d, J = 9.1 Hz, 2H, Ar); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  20.4, 42.3 (2C), 123.4 (2C), 127.0 (2C), 143.2, 148.3, 152.7. *Anal.* calcd for C<sub>10</sub>H<sub>11</sub>N<sub>3</sub>O<sub>2</sub>: C, 58.53; H, 5.40; N, 20.48. Found: C, 58.61; H, 5.45; N, 20.48.



**1-Methyl-2-phenyl-1,4,5,6-tetrahydropyrimidine** (**4**): Benzaldehyde (1.06 g, 10 mmol) and *N*-methyl propandiamine (0.97 g, 11 mmol) was subjected to general procedure as described above (without further purification after demineralisation). Yellow oil (1.49 g, 85%); IR (neat) cm<sup>-1</sup>: 1600 (C=N); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  1.92-1.98 (m, 2H, CH<sub>2</sub>), 2.74 (s, 3H, NCH<sub>3</sub>), 3.27 (t, *J* = 5.6 Hz, 2H, CH<sub>2</sub>), 3.51 (t, *J* = 5.2 Hz, 2H, CH<sub>2</sub>), 7.32-7.40 (m, 5H, Ar); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  22.0, 40.3, 45.0, 49.0, 127.9 (2C), 128.0 (2C), 128.4, 138.1, 159.1; HRMS (EI): *m/z* calcd for C<sub>11</sub>H<sub>13</sub>N<sub>2</sub> [M - 1]<sup>-</sup> 173.1084; found: 173.1082.



Procedure for the C-H Hydroxylation (Table 1, entry 10). Synthesis General of 2,3-Dihydro-1H-9-oxa-4,10a-diazaphenanthren-10-one (3a): DMF (0.83 mL) and water (4.5 µL, 0.25 mmol) were added to a flask containing 2-phenyltetrahydropyrimidine (40.1 mg, 0.25 mmol) and Cu(OAc)<sub>2</sub> (45.4 mg, 0.25 mmol) under O<sub>2</sub> atmosphere. After stirring at 130 °C for 20 min, TMEDA (N,N,N',N'-tetramethylethylenediamine) (150 µL, 1 mmol) was added, and the mixture was stirred for 1 min at the same temperature. The reaction mixture was concentrated in vacuo. To a stirring solution of this residue and TMEDA (150 µL, 1 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (16.6 mL) was added dropwise a solution of triphosgene (77.9 mg, 0.26 mmol) in CH<sub>2</sub>Cl<sub>2</sub>(1.7 mL) at 0 °C. After stirring at room temperature for 1h, the mixture was quenched with sat. NH<sub>4</sub>Cl, and CH<sub>2</sub>Cl<sub>2</sub> was removed in vacuo. The resulting mixture was made basic with 28% NH<sub>4</sub>OH. The whole was extracted with EtOAc. The extract was washed with sat. NH<sub>4</sub>Cl-28% NH<sub>4</sub>OH, brine, and dried over MgSO<sub>4</sub>. The filtrate was concentrated in vacuo. The residue was purified by flash chromatography over silica gel with *n*-hexane-EtOAc (1:1) to give 3a as colorless crystals (35.2 mg, 70%): mp 146–147 °C (from CHCl<sub>3</sub>–n-hexane); IR (neat) cm<sup>-1</sup>: 1730 (C=O), 1647 (C=N); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  1.98-2.04 (m, 2H, CH<sub>2</sub>), 3.68 (t, *J* = 5.6 Hz, 2H, CH<sub>2</sub>), 3.95 (t, J = 6.0 Hz, 2H, CH<sub>2</sub>), 7.14 (d, J = 8.3 Hz, 1H, Ar), 7.23-7.30 (m, 1H, Ar), 7.48-7.51 (m, 1H, Ar), 8.02 (d, J = 7.8 Hz, 1H, Ar); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  20.3, 42.5, 44.1, 116.2, 125.0, 125.5, 127.8, 129.0, 132.9, 147.5, 150.4; HRMS (FAB): m/z calcd for C<sub>11</sub>H<sub>11</sub>N<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup> 203.0821; found: 203.0813.



**7-Methoxy-2,3-dihydro-***1H***-9-oxa-4,10a-diazaphenanthren-10-one** (**3b**): 2-(4-Methoxy-phenyl)-1,4,5,6-tetrahydropyrimidine (47.6 mg, 0.25 mmol) was subjected to general procedure as described above. Pale yellow solid (37.3 mg, 64%): mp 160–161 °C (from CHCl<sub>3</sub>–*n*-hexane); IR (neat) cm<sup>-1</sup>: 1731 (C=O), 1650 (C=N); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  1.97-2.02 (m, 2H, CH<sub>2</sub>), 3.64 (t, *J* = 5.7 Hz, 2H, CH<sub>2</sub>), 3.85 (s, 3H, OCH<sub>3</sub>), 3.92 (t, *J* = 6.0 Hz, 2H, CH<sub>2</sub>), 6.59 (d, *J* = 2.3 Hz, 1H, Ar), 6.79 (dd, *J* = 8.6, 2.3 Hz, 1H, Ar), 7.90 (d, *J* = 8.6 Hz, 1H, Ar); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  20.5, 42.5, 44.0, 55.7, 100.0, 108.8, 112.6, 126.6, 142.7, 147.8, 151.7, 163.3; HRMS (FAB): *m/z* calcd for C<sub>12</sub>H<sub>13</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup> 233.0926; found: 233.0921.



**7-Methyl-2,3-dihydro**-*1H*-4,10a-diaza-9-oxaphenanthren-10-one (3c): 2-(4-Tolyl)-1,4,5,6-tetrahydropyrimidine (43.6 mg, 0.25 mmol) was subjected to general procedure as described above. Yellow crystals (32.8 mg, 61%): mp 153–154 °C (from CHCl<sub>3</sub>–*n*-hexane); IR (neat) cm<sup>-1</sup>: 1736 (C=O), 1650 (C=N); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  1.98-2.02 (m, 2H, CH<sub>2</sub>), 2.40 (s, 3H, CH<sub>3</sub>), 3.66 (t, *J* = 5.4 Hz, 2H, CH<sub>2</sub>), 3.93 (t, *J* = 6.0 Hz, 2H), 6.93 (s, 1H, Ar), 7.05 (d, *J* = 8.0 Hz, 1H, Ar), 7.88 (d, *J* = 8.0 Hz, 1H, Ar); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  20.4, 21.5, 42.5, 44.1, 113.4, 116.2, 125.2, 126.2, 143.0, 144.0, 148.0, 150.4; HRMS (FAB): *m/z* calcd for C<sub>12</sub>H<sub>13</sub>N<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup> 217.0977; found: 217.0979.



**7-Bromo-2,3-dihydro-***1H***-4,10a-diaza-9-oxaphenanthren-10-one** (3d): 2-(4-Bromophenyl)-1,4,5,6-tetrahydropyrimidine (59.8 mg, 0.25 mmol) was subjected to general procedure as described above. Pale yellow crystals (31.3 mg, 45%): mp 206–207 °C (from CHCl<sub>3</sub>–*n*-hexane); IR (neat) cm<sup>-1</sup>: 1729 (C=O), 1651 (C=N); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  1.98-2.03 (m, 2H, CH<sub>2</sub>), 3.65 (t, *J* = 5.7 Hz, 2H, CH<sub>2</sub>), 3.93 (t, *J* = 6.0 Hz, 2H, CH<sub>2</sub>), 7.31 (d, *J* = 1.7 Hz, 1H, Ar), 7.37 (dd, *J* = 8.6, 1.7 Hz, 1H, Ar), 7.87 (d, *J* = 8.6 Hz, 1H, Ar); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  20.3, 42.6, 44.2, 115.2, 119.4, 126.4, 126.8, 128.4, 142.1, 147.0, 150.7; HRMS (FAB): *m/z* calcd for C<sub>11</sub>H<sub>10</sub>BrN<sub>2</sub>O<sub>2</sub> [M + H, <sup>79</sup>Br]<sup>+</sup> 280.9926; found: 280.9922.



**7-(Methoxycarbonyl)-2,3-dihydro-***1H***-4,10a-diaza-9-oxaphenanthren-10-one** (**3e**): 2-[(4-Methoxycarbonyl)phenyl]-1,4,5,6-tetrahydropyrimidine (54.6 mg, 0.25 mmol) was subjected to general procedure as described above. Pale yellow crystals (30.2 mg, 46%): mp 136–137 °C (from CHCl<sub>3</sub>–*n*-hexane); IR (neat) cm<sup>-1</sup>: 1741 (C=O), 1718 (C=O), 1644 (C=N); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  2.00-2.05 (m, 2H, CH<sub>2</sub>), 3.70 (t, *J* = 5.4 Hz, 2H, CH<sub>2</sub>), 3.94-3.96 (m, 5H, CH<sub>2</sub>,OMe), 7.78 (d, *J* = 1.4 Hz, 1H, Ar), 7.88 (dd, *J* = 8.6, 1.4 Hz, 1H, Ar), 8.09 (d, *J* = 8.6 Hz, 1H, Ar); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  20.2, 42.5, 44.4, 52.6, 117.6, 119.7, 125.6, 125.8, 134.3, 142.2, 147.1, 150.2, 165.4; HRMS (FAB): *m/z* calcd for C<sub>13</sub>H<sub>13</sub>N<sub>2</sub>O<sub>4</sub> [M + H]<sup>+</sup> 261.0875; found: 261.0874.



**7-(Trifuluoromethyl)-2,3-dihydro-***1H***-4,10a-diaza-9-oxaphenanthren-10-one** (**3f**): 2-[4-(Trifuluoromethyl)phenyl]-1,4,5,6-tetrahydropyrimidine (57.1 mg, 0.25 mmol) was subjected to general procedure as described above. Yellow solid (28.8 mg, 43%): mp 141–142 °C (from CHCl<sub>3</sub>–*n*-hexane); IR (neat) cm<sup>-1</sup>: 1739 (C=O), 1650 (C=N); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  2.00-2.05 (m, 2H, CH<sub>3</sub>), 3.70 (t, *J* = 5.7 Hz, 2H, CH<sub>2</sub>), 3.95 (t, *J* = 6.0 Hz, 2H, CH<sub>2</sub>), 7.40 (d, *J* = 1.1 Hz, 1H, Ar), 7.49 (dd, *J* = 8.0, 1.1 Hz, 1H, Ar), 8.15 (d, *J* = 8.0 Hz, 1H, Ar); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  20.3, 42.7, 44.5, 113.9 (q, *J* = 4.1 Hz), 119.3, 121.6 (q, *J* = 3.6 Hz), 124.5, 126.7, 134.7 (q, *J* = 33.7 Hz), 141.8, 146.9, 150.4; <sup>19</sup>F NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  –63.0; HRMS (FAB): *m/z* calcd for C<sub>12</sub>H<sub>10</sub>F<sub>3</sub>N<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup> 271.0694; found: 271.0692.



**7-Nitro-2,3-dihydro-***1H***-4,10a-diaza-9-oxaphenanthren-10-one** (**3g**): 2-(4-Nitrophenyl)-1,4,5,6-tetrahydropyrimidine (51.3 mg, 0.25 mmol) was subjected to general procedure as described above. Yellow crystals (11.9 mg, 19%): mp 235–236 °C (from CHCl<sub>3</sub>–*n*-hexane); IR (neat) cm<sup>-1</sup>: 1732 (C=O), 1641 (C=N), 1531 (NO<sub>2</sub>), 1349 (NO<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  2.01-2.07 (m, 2H, CH<sub>2</sub>), 3.72 (t, *J* = 5.6 Hz, 2H, CH<sub>2</sub>), 3.96 (t, *J* = 6.0 Hz, 2H, CH<sub>2</sub>), 8.00 (d, *J* = 2.2 Hz, 2H, Ar), 8.08 (dd, *J* = 8.8, 2.2 Hz, 1H, Ar), 8.22 (d, *J* = 8.8 Hz, 1H, Ar); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  20.1, 42.6, 44.5, 112.2, 119.4, 121.4, 127.1, 141.3, 146.4, 150.3, 150.5; HRMS (FAB): *m/z* calcd for C<sub>11</sub>H<sub>10</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup> 248.0671; found: 248.0670.



**C-H Amidation with BocNH<sub>2</sub>. Synthesis of 3,4-Dihydro-2***H***-pyrimido[1,2-***c***]quinazolin-6(7***H***)-one (7a): DMF (0.83 mL) was added to a flask containing 2-phenyltetrahydropyrimidine (40.1 mg, 0.25 mmol), Cu(OAc)<sub>2</sub> (45.4 mg, 0.25 mmol) and** *tert***-butyl carbamate (87.9 mg, 0.75 mmol) under O<sub>2</sub> atmosphere. After stirring at 100 °C for 40 min, the mixture was concentrated in vacuo. The residue was purified by flash chromatography over aluminium oxide with CHCl<sub>3</sub> [gradationally to CHCl<sub>3</sub>–MeOH (99:1)] to give <b>7a** as a white solid (26.5 mg, 53%): mp 250–251 °C (from CHCl<sub>3</sub>–*n*-hexane); IR (neat) cm<sup>-1</sup>: 1682 (C=O), 1616 (C=N); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  1.95-2.00 (m, 2H, CH<sub>2</sub>), 3.67 (t, *J* = 5.6 Hz, 2H, CH<sub>2</sub>), 3.94 (t, *J* = 6.0 Hz, 2H, CH<sub>2</sub>), 6.86 (d, *J* = 8.0 Hz, 1H, Ar), 7.09-7.13 (m, 1H, Ar), 7.38-7.42 (m, 1H, Ar), 8.07 (d, *J* = 8.0 Hz, 1H, Ar), 8.30 (br s, 1H, NH); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  20.3, 40.8, 44.5, 114.6, 116.5, 123.0, 125.8, 132.0, 136.5, 145.7, 151.2; HRMS (FAB): *m/z* calcd for C<sub>11</sub>H<sub>12</sub>N<sub>3</sub>O [M + H]<sup>+</sup> 202.0980; found: 202.0988.



C-H Amidation with TsNH<sub>2</sub>. Synthesis of 7-Tosyl-3,4-dihydro-2H-pyrimido[1,2-c]quinazolin-6(7H)-one (7b): DMF (0.83 mL) was added to a flask containing 2-phenyltetrahydropyrimidine (40.1 mg, 0.25 mmol), Cu(OAc)<sub>2</sub> (45.4 mg, 0.25 mmol) and p-toluene sulfonamide (85.6 mg, 0.5 mmol) under O<sub>2</sub> atmosphere. After stirring at 130 °C for 20 min, the mixture was concentrated in vacuo followed by flash chromatography over aluminium oxide with CHCl3-MeOH (95:5) to give ortho-amidated compound as a crude material. To a stirring solution of the ortho-amidated compound and Et<sub>3</sub>N (145 µL, 1.0 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (16.6 mL) was added dropwise a solution of triphosgene (77.9 mg, 0.26 mmol) in CH<sub>2</sub>Cl<sub>2</sub>(1.7 mL) at 0 °C. After stirring at room temperature for 1h, the mixture was quenched with sat. NaHCO<sub>3</sub> and CH<sub>2</sub>Cl<sub>2</sub> was removed in vacuo. The whole was extracted with EtOAc. The extract was washed with sat. NaHCO<sub>3</sub>, brine, and dried over MgSO<sub>4</sub>. The filtrate was concentrated in vacuo. The residue was purified by flash chromatography over silica gel with n-hexane-EtOAc (1:1) to give 7b as colorless crystals (42.2 mg, 47%): mp 159–161 °C (from CHCl<sub>3</sub>–*n*-hexane); IR (neat) cm<sup>-1</sup>: 1695 (C=O), 1644 (C=N); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  1.85-1.91 (m, 2H, CH<sub>2</sub>), 2.46 (s, 3H, CH<sub>3</sub>), 3.63 (t, J = 5.7 Hz, 2H, CH<sub>2</sub>), 3.75 (t, J = 6.2 Hz, 2H, CH<sub>2</sub>), 7.27-7.31 (m, 1H, Ar), 7.37 (d, J = 8.3 Hz, 2H, Ar), 7.48-7.53 (m, 1H, Ar), 7.87 (d, J = 8.5 Hz, 1H, Ar), 8.03 (d, J = 8.3 Hz, 2H, Ar), 8.07 (dd, J = 8.0, 1.7 Hz, 1H, Ar); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  20.5, 21.8, 41.8, 44.6, 120.3, 121.0, 125.7, 126.4, 128.4 (2C), 129.8 (2C), 131.3, 134.6, 136.7, 144.5, 145.4, 148.3; HRMS (FAB): m/z calcd for C<sub>18</sub>H<sub>18</sub>N<sub>3</sub>O<sub>3</sub>S [M + H]<sup>+</sup> 356.1069; found: 356.1074.





DATIM Tue Dec 09 14:45:33 2008 100.40 MHz 125.00 KHz 10500.00 Hz 32768 27118.64 Hz 200 1.2083 sec 1.7920 sec 5.10 usec 25.5 c 77.00 ppm 0.12 Hz



































































